Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 76Triple Negative Breast Neoplasms 12Ovarian Neoplasms 7Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms, Male 4Pancreatic Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Kidney Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Melanoma 1

Interventions

pembrolizumab 13Paclitaxel 7Carboplatin 7Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6Gemcitabine 5Capecitabine 5olaparib 2liposomal doxorubicin 2lenvatinib 2Doxorubicin 2Cyclophosphamide 2eribulin 1efineptakin alfa 1Vinorelbine 1Saline Solution 1Pemetrexed 1Oxaliplatin 1Glucose 1Fluorouracil 1Epirubicin 1Docetaxel 1Cisplatin 1Bevacizumab 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × liposomal doxorubicin × Breast × Clear all
NCT06312176 2026-05-22

MK-2870-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,200 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
340 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡